Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2011-12-20
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 9
- Registration Number
- NCT01028781
- Locations
- 🇺🇸
UNC Chapel Hill, Chapel Hill, North Carolina, United States
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT00966693
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
- Conditions
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT00964496
Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
- Conditions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 37
- Registration Number
- NCT00958854
- Locations
- 🇬🇧
Cancer Research UK and University College London Cancer Trials Centre, Exeter, England, United Kingdom
Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2012-02-27
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1
- Registration Number
- NCT00953615
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Cigdem Sahinbas YILMAZ
- Target Recruit Count
- 122
- Registration Number
- NCT00934154
- Locations
- 🇹🇷
Ankara Numune Education and Research Hospital,Hematology Department, Ankara, Turkey
🇹🇷Baskent University School of Medicine Education and Research Hospital, Hematology Department, Adana, Turkey
🇹🇷Gazi University School of Medicine, Hematology Department, Ankara, Turkey
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT00921531
- Locations
- 🇨🇳
Liver Cancer Institute, Shanghai, Shanghai, China
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 160
- Registration Number
- NCT00871013
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 90
- Registration Number
- NCT00869232
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- Valme University Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT00856804
- Locations
- 🇪🇸
Hospital de Valme, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.